Kabi Commits To Biosimilars Development

 
• By Aidan Fry
  
Kabil
Attendees of the official inauguration of Fresenius Kabi's biosimilars research and development center in Eysins, Switzerland, included the company's CEO, Mats Henriksson (third left) • Source: Fresenius Kabi

More from Biosimilars

More from Products